Endo Assess Cvd Risk Guidelines Nontransgender Adults Gender Affirming Hormone Therapy

---
name: endo-assess-cvd-risk-guidelines-nontransgender-adults-gender-affirming-hormone-therapy
description: This skill advises assessing cardiovascular risk using guidelines for nontransgender adults in transgender patients receiving gender-affirming hormone therapy. Trigger phrases include "Transgender patient on hormone therapy", "CV risk assessment in gender-affirming hormone treatment", and "Applying standard risk calculators to transgender individuals".
---

# Assess cardiovascular risk by guidelines for nontransgender adults in gender-affirming hormone therapy

## STEP 1 — Gather Information
Collect patient age, sex assigned at birth (for risk calculator), hormone therapy type (estrogen for transwomen, testosterone for transmen) and duration, traditional risk factors (smoking status, diabetes status, hypertension and treatment, systolic blood pressure), lipid panel (total cholesterol, HDL-C, LDL-C, triglycerides), and family history of premature ASCVD.

## STEP 2 — Rule In / Rule Out
Rule in/out established atherosclerotic cardiovascular disease (ASCVD) or long-standing diabetes. If present, proceed to consider statin therapy irrespective of risk score; if absent, proceed to 10-year risk assessment.

## STEP 3 — Classify or Stratify
Calculate 10-year ASCVD risk using the Pooled Cohort Equations. Classify risk as low (<5%), borderline (5–7.4%), intermediate (7.5–19.9%), or high (≥20%). Assess for risk-enhancing factors (e.g., family history of premature ASCVD, elevated lipoprotein(a), metabolic syndrome, chronic kidney disease, inflammatory conditions, high-risk race/ethnicity).

## STEP 4 — Decide
For low risk (<5%) and CAC=0, no statin; for borderline risk (5–7.4%), consider statin if risk-enhancing factors present or CAC score >0; for intermediate risk (7.5–19.9%), recommend moderate- to high-intensity statin; for high risk (≥20%), recommend high-intensity statin. If risk‑treatment decision uncertain in borderline/intermediate risk, consider coronary artery calcium (CAC) scoring to reclassify risk.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on hormone therapy effects to modify risk calculator inputs; use sex assigned at birth for Pooled Cohort Equations due to lack of gender‑specific data. Hormone therapy may alter lipids (↑ TG with estrogen, ↓ HDL with testosterone) but still apply nontransgender guidelines. Avoid delaying statin initiation based solely on hormone therapy. Watch for drug interactions (e.g., estrogen may increase statin levels). Do not use CAC=0 to avoid statin in familial hypercholesterolemia, active smoking, or advanced diabetes.

## Concrete Clinical Example
A 45‑year‑old transwoman on estrogen therapy for 2 years, no diabetes, non‑smoker, BP 128/76 mm Hg, total cholesterol 200 mg/dL, HDL‑C 55 mg/dL, LDL‑C 120 mg/dL. 10‑year ASCVD risk ≈6.5 % (borderline). She has a first‑degree relative with premature CAD (risk‑enhancing factor) and CAC score 120. Decision: initiate moderate‑intensity statin.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674